Camoteskimab not checked

Apollo Therapeutics Ltd · AEVI-007 · APL-9109

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
4 in total · 1 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
Tested for
Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic
Main trialPhase 2
“This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.”In the company’s words, NCT07599813 on ClinicalTrials.gov
Other names
AEVI-007 · APL-9109 · AVTX-007 · CERC-007 · MEDI2338

Other drugs for Atopic Dermatitis

All 90 drugs for Atopic Dermatitis

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 31 Oct 2027 A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
Phase 2Completed 26 Mar 2025 A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis
Phase 1Completed 30 Mar 2022 Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma
Phase 1Terminated 24 May 2022 A Study to Evaluate Camoteskimab in Participants With Still's Disease
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Camoteskimab

Following is part of Solo: you see every change to Camoteskimab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in